Effects of Silodosin on Lower Urinary Tract Symptoms in Patients with Benign Prostatic Hyperplasia: Evaluation by Frequency/Volume Chart

Watanabe, Miho; Yamanishi, Tomonori; Mizuno, Tomoya; Tatsumiya, Katsuhisa; Masuda, Akinori; Honda, Minoru; Uchiyama, Tomoyuuki; Sakakibara, Ryuji; Yoshida, Keisuke

doi:10.1111/j.1757-5672.2010.00059.x

Cited by 7 publications

(11 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although there might be controversy regarding the effects of α 1 ‐AR antagonists on storage or voiding dysfunction in terms of α 1A ‐AR selectivity, silodosin was found to be effective not only for voiding symptoms, but also storage symptoms in the present study. In the frequency volume chart, improvements in daytime and night‐time frequency, as well as increases in the mean and maximum voided volume, have been reported . In urodynamic studies, disappearance or improvements in detrusor overactivity, and reduction of the grade of obstruction on the ICS nomogram, have also been reported .…”

Section: Discussionmentioning

confidence: 90%

Six‐year follow up of silodosin monotherapy for the treatment of lower urinary tract symptoms suggestive of benign prostatic hyperplasia: What are the factors for continuation or withdrawal?

et al. 2015

Self Cite

View full text Add to dashboard Cite

Objectives: To investigate the factors for continuation or withdrawal as an extension of a prospective study of silodosin monotherapy for the treatment of lower urinary tract symptoms suggestive of benign prostatic hyperplasia for more than 6 years. Methods: A total of 104 patients (age 71.5 AE 8.2 years) were enrolled in the present study. The mean prostate volume was 44.1 AE 23.9 mL. International Prostate Symptom Score, quality of life index, maximum flow rate, and postvoid residual urine volume were determined at baseline, and at 1, 3, 6 and 12-72 months after treatment. Results: Adverse events were noted in 14 patients (13.5%), and the most frequent adverse event was ejaculatory dysfunction (5.8%). Withdrawal was noted in 78 patients, and 26 patients (25.0%) were still taking silodosin at 72 months (continuing group). The reasons for withdrawals were: unknown in 27 patients (26.0%), adverse events in nine patients (8.7%), unsatisfactory effects in 30 patients (28.8%) and satisfied with the current condition for six patients (5.8%). In 30 patients who withdrew because of unsatisfactory effects, surgery was carried out in 21 patients (surgery group). The baseline total International Prostate Symptom Score did not differ between the continuing group and the surgery group. However, patients with the continuing group had significantly smaller baseline prostate volume, and lower baseline quality of life index and prostate-specific antigen, than in the surgery group. The mean total International Prostate Symptom Score, quality of life index and maximum flow rate improved significantly at 1 month, and remained stable up to 72 months. Conclusions: The withdrawal rate was higher in patients with a larger prostate. The effects of silodosin for lower urinary tract symptoms was immediate and stable up to 72 months.

show abstract

Section: Discussionmentioning

confidence: 90%

Six‐year follow up of silodosin monotherapy for the treatment of lower urinary tract symptoms suggestive of benign prostatic hyperplasia: What are the factors for continuation or withdrawal?

et al. 2015

Self Cite

View full text Add to dashboard Cite

show abstract

“…Furthermore, N‐QOL score ≤90 might indicate the risk of nocturia twice or more. It has been reported that night‐time voiding twice or more at night can be highly bothersome and thus symptomatic . Therefore, N‐QOL <90 might be influenced on the worsening of daily life.…”

Section: Discussionmentioning

confidence: 91%

Nocturia Quality‐of‐Life questionnaire is a useful tool to predict nocturia and a risk of falling in Japanese outpatients: A cross‐sectional survey

et al. 2013

Self Cite

View full text Add to dashboard Cite

Abbreviations & Acronyms BPH = benign prostatic hyperplasia CI = confidence interval N-QOL = Nocturia Quality-of-Life questionnaire OAB = overactive bladder OAB-q = overactive bladder questionnaire OABSS = overactive bladder symptom score QOL = quality of life ROC = receiver operating characteristic Objectives: To evaluate the Japanese version of the Nocturia Quality-of-Life questionnaire for prediction of night-time voiding and risk of falling. Methods: A survey was carried out from October 2008 to June 2009 in outpatients at 15 general hospitals and 80 general clinics in Tochigi, Japan, using the Nocturia Quality-of-Life questionnaire, overactive bladder symptom score and self-administered questionnaires on night-time symptoms (awakening, number of voids, incontinence and falling). Results: The survey was completed by 2494 participants (1154 men, 1208 women; mean age 63.2 ± 15.1 years). Overactive bladder was diagnosed in 625 participants (25.1%) according to the Japanese overactive bladder guideline using overactive bladder symptom score. Awakening during sleep was reported by 80.1% of the participants, and 70.4% awakened to go to the toilet. The mean Nocturia Quality-of-Life score was 86.8 ± 16.9. The Nocturia Qualityof-Life score was lower in patients with overactive bladder, benign prostatic hyperplasia, diabetes, hypertension and cardiovascular diseases. The Nocturia Quality-of-Life score was significantly decreased in patients with night-time symptoms (P < 0.001). Nocturia Qualityof-Life scores and those for subdomains were correlated with overactive bladder symptom score. Nocturia Quality-of-Life ≤90 had 63.1% sensitivity and 78.6% specificity in indicating night-time voiding more than twice, and Nocturia Quality-of-Life questionnaire ≤80 had 70.2% sensitivity and 79.5% specificity in indicating the probability of falling at least once. Logistic analysis showed that 10-year increase in age and overactive bladder in all participants were significant risk factors for Nocturia Quality-of-Life ≤90. Conclusions:The Nocturia Quality-of-Life questionnaire represents a useful tool to predict nocturia and risk of falling in Japanese patients.Key words: falling, nocturia, Nocturia Quality-of-Life questionnaire, overactive bladder, overactive bladder symptom score. IntroductionDemographic studies have shown that the frequency of nocturia increases with age, 1-3 and that increased night-time frequency of voiding leads to bone fracture, decreased QOL and increased risk of death in the elderly.4,5 These findings have caused considerable interest in this condition, but in clinical settings many elderly people accept nocturia as an aging symptom, and the degree to which it is viewed as an irritant varies from person to person. Thus, for the treatment of nocturia, an appropriate evaluation of the effect of nocturia on daily QOL is required, in addition to an understanding of the pathology and symptoms.The Medical Outcomes Study Short Form-36 is a generic questionnaire that cannot detect the influence of nocturia on QOL,...

show abstract

“…benign prostatic hyperplasia, mirabegron, overactive, tadalafil, urinary bladder 1 | INTRODUCTION α 1 -Blockers have been used for the first-line treatment of lower urinary tract symptoms suggestive of benign prostatic hyperplasia ("LUTS/BPH"). [1][2][3][4] These drugs may relieve voiding symptoms as well as storage symptoms. [1][2][3][4] However, patients may still have persistent storage symptoms despite α 1 -blocker treatment.…”

Section: Introductionmentioning

confidence: 99%

A randomized controlled study of the efficacy of tadalafil monotherapy versus combination of tadalafil and mirabegron for the treatment of persistent overactive bladder symptoms in men presenting with lower urinary tract symptoms (CONTACT Study)

Yamanishi

Kaga

Sakata³

et al. 2020

Neurourology and Urodynamics

Self Cite

View full text Add to dashboard Cite

A randomized controlled study of the efficacy of tadalafil monotherapy versus combination of tadalafil and mirabegron for the treatment of persistent overactive bladder symptoms in men presenting with lower urinary tract symptoms (CONTACT Study) Abstract Aim: To evaluate efficacy and safety of combination of tadalafil + mirabegron for overactive bladder/benign prostatic hyperplasia (OAB/BPH). Methods: Male patients with lower urinary tract symptoms (50 to 89 years), with remaining OAB symptoms even after administering tadalafil for more than 8 weeks were randomly assigned to either tadalafil monotherapy group (5 mg/day) or tadalafil/mirabegron combination therapy group (5 mg/50 mg/day). The primary endpoint was change from baseline in total OAB symptom score (OABSS) at week 12. The secondary endpoints were changes in International Prostate Symptom Score (IPSS), NIH-chronic prostatitis symptom index (NIH-CPSI), and micturition chart parameters at weeks 4 and 12.Results: A total of 176 patients were randomized to either monotherapy (87 patients) or combination therapy (89 patients). The baseline characteristics of patients in the two groups were similar. The total OABSS (95% confidence interval) of combination therapy was significantly decreased by 1.78 (1.05-2.50) points compared with that of monotherapy (P < .001). Changes from baseline in OABSS nighttime voiding score, urgency score, urgency incontinence score, IPSS storage subscores, NIH-CPSI total score, and numbers of voids, nighttime-voids, and urgency episodes/day in micturition chart were significantly reduced in combination therapy (all P < .001). Patient-reported outcome was significantly more satisfactory in combination therapy than in monotherapy (P < .001). One moderate adverse event (pain in hip joint) with hardly presumed causal relationship with therapy and seven mild adverse events were noted in monotherapy and combination therapy group, respectively.---

show abstract

Effects of Silodosin on Lower Urinary Tract Symptoms in Patients with Benign Prostatic Hyperplasia: Evaluation by Frequency/Volume Chart

Abstract: Silodosin appears to be effective for both storage and voiding symptoms by increasing bladder capacity in patients with LUTS/BPH.

Cited by 7 publications

References 33 publications

Six‐year follow up of silodosin monotherapy for the treatment of lower urinary tract symptoms suggestive of benign prostatic hyperplasia: What are the factors for continuation or withdrawal?

Six‐year follow up of silodosin monotherapy for the treatment of lower urinary tract symptoms suggestive of benign prostatic hyperplasia: What are the factors for continuation or withdrawal?

Nocturia Quality‐of‐Life questionnaire is a useful tool to predict nocturia and a risk of falling in Japanese outpatients: A cross‐sectional survey

A randomized controlled study of the efficacy of tadalafil monotherapy versus combination of tadalafil and mirabegron for the treatment of persistent overactive bladder symptoms in men presenting with lower urinary tract symptoms (CONTACT Study)

Contact Info

Product

Resources

About